Yang Kaiying,Peng Suhua,Chen Siyuan,et al.Current status of diagnosing and treating infantile hepatic hemangioma[J].Journal of Clinical Pediatric Surgery,2020,19(08):746-751.[doi:10.3969/j.issn.1671-6353.2020.08.016]
婴幼儿肝血管瘤诊治现状
- Title:
- Current status of diagnosing and treating infantile hepatic hemangioma
- Keywords:
- Infant; Hepatic Hemangioma; Diagnosis and Treatment
- 分类号:
- R657.3;R726
- 摘要:
- 婴幼儿肝血管瘤（infantile hepatic hemangioma，IHH）是儿童肝脏最常见的良性肿瘤，临床上分为3类：局灶性、多发性及弥散性。不同类型IHH的临床特点及症状严重性不同，其中弥散性IHH常合并消耗性甲状腺功能减退、心力衰竭和（或）腹腔间隔室综合征等严重并发症。近年研究表明，皮肤多发血管瘤和弥散性病变分别是其发病和致死的危险因素，口服普萘洛尔治疗多发性与弥散性IHH疗效显著。本文将从IHH的临床特征、并发症、危险因素、影像学特点、病理学特征及治疗等方面进行综述，为临床诊治提供参考。
- Abstract:
- As the most common benign tumor of liver in children, infantile hepatic hemangioma (IHH) may be classified into three morphologic patterns of focal, multifocal and diffuse. The clinical characteristics and symptoms of 3 different subtypes of IHH vary widely. Major complications of diffuse IHH include consumptive hypothyroidism, heart failure and abdomen compartment syndrome. As demonstrated by recent studies, two risk factor for IHH and death are multiple cutaneous infantile hemangiomas and diffuse IHH. Oral propranolol is efficacious for multifocal and diffuse IHHs. For providing guidance for diagnosing and treating IHH, this review focuses upon the clinical characteristics, major complications, risk factors, imaging manifestations, pathological features and treatments of IHH.
参考文献/References:
1 Hsi Dickie B,Fishman SJ,Azizkhan RG.Hepatic vascular tumors[J].Semin Pediatr Surg,2014,23(4):168-172.DOI:10.1053/j.sempedsurg.2014.06.018.
2 Kassarjian A,Zurakowski D,Dubois J,et al.Infantile hepatic hemangiomas:clinical and imaging findings and their correlation with therapy[J].AJR Am J Roentgenol,2004,182(3):785-795.DOI:10.2214/ajr.182.3.1820785.
3 Christison-Lagay ER,Burrows PE,Alomari A,et al.Hepatic hemangiomas:subtype classification and development of a clinical practice algorithm and registry[J].J Pediatr Surg,2007,42(1):62-67;discussion67-68.DOI:10.1016/j.jpedsurg.2006.09.041.
4 Dasgupta R,Fishman SJ.ISSVA classification[J].Semin Pediatr Surg,2014,23(4):158-161.DOI:10.1053/j.sempedsurg.2014.06.016.
5 Kulungowski AM,Alomari AI,Chawla AA,et al.Lessons from a liver hemangioma registry:subtype classification[J].J Pediatr Surg,2012,47(1):165-170.DOI:10.1016/j.jpedsurg.2011.10.037.
6 Rialon KL,Murillo R,Fevurly RD,et al.Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas[J].J Pediatr Surg,2015,50(5):837-841.DOI:10.1016/j.jpedsurg.2014.09.056.
7 Rialon KL,Murillo R,Fevurly RD,et al.Impact of screening for hepatic hemangiomas in patients with multiple cutaneous infantile hemangiomas[J].Pediatric Dermatology,2015,32(6):808-812.DOI:10.1111/pde.12656.
8 Ji Y,Chen S,Xiang B,et al.Clinical features and management of multifocal hepatic hemangiomas in children:a retrospective study[J].Sci Rep,2016,6:31744.DOI:10.1038/srep31744.
9 Li K,Wang Z,Liu Y,et al.Fine clinical differences between patients with multifocal and diffuse hepatic hemangiomas[J].J Pediatr Surg,2016,51(12):2086-2090.DOI:10.1016/j.jpedsurg.2016.09.045.
10 Hernandez F,Navarro M,Encinas JL,et al.The role of GLUT1 immunostaining in the diagnosis and classification of liver vascular tumors in children[J].J Pediatr Surg,2005,40(5):801-804.DOI:10.1016/j.jpedsurg.2005.01.046.
11 Roebuck D,Sebire N,Lehmann E,et al.Rapidly involuting congenital haemangioma (RICH) of the liver[J].PediatrRadiol,2012,42(3):308-314.DOI:10.1007/s00247-011-2268-z.
12 Gnarra M,Behr G,Kitajewski A,et al.History of the infantile hepatic hemangioma:From imaging to generating a differential diagnosis[J].World J Clin Pediatr,2016,5(3):273-280.DOI:10.5409/wjcp.v5.i3.273.
13 Isaacs H Jr.Fetal and neonatal hepatic tumors[J].J Pediatr Surg,2007,42(11):1797-1803.DOI:10.1016/j.jpedsurg.2007.07.047.
14 Huang SA,Tu HM,Harney JW,et al.Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas[J].N Engl J Med,2000,343(3):185-189.DOI:10.1056/NEJM200007203430305.
15 Varrasso G,Schiavetti A,Lanciotti S,et al.Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma:a case report[J].Hepatology,2017,66(1):283-285.DOI:10.1002/hep.29028.
16 Higuchi S,Takagi M,Hasegawa Y.Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas[J].Endocr J,2017,64(6):639-643.DOI:10.1507/endocrj.EJ16-0559.
17 Jabbar A,Pingitore A,Pearce SH,et al.Thyroid hormones and cardiovascular disease[J].Nat Rev Cardiol,2017,14(1):39-55.DOI:10.1038/nrcardio.2016.174.
18 De Waele JJ,De Laet I,Malbrain ML.Understanding abdominal compartment syndrome[J].Intensive Care Med,2016,42(6):1068-1070.DOI:10.1007/s00134-015-4089-2.
19 Warren,Diaz L,Levy M.Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol[J].Pediatr Dermatol,2017,34(5):e286-e287.DOI:10.1111/pde.13219.
20 Zhang Z,Chen HJ,Yang WJ,et al.Infantile hepatic hemangioendothelioma:a clinicopathologic study in a Chinese population[J].World J Gastroenterol,2010,16(36):4549-4557.DOI:10.3748/wjg.v16.i36.4549.
21 Fernandez-Pineda I,Cabello-Laureano R.Differential diagnosis and management of liver tumors in infants[J].World J Hepatol,2014,6(7):486-495.DOI:10.4254/wjh.v6.i7.486.
22 Sharma D,Subbarao G,Saxena R.Hepatoblastoma[J].Semin Diagn Pathol,2017,34(2):192-200.DOI:10.1053/j.semdp.2016.12.015.
23 Stringer MD,Alizai NK.Mesenchymal hamartoma of the liver:a systematic review[J].J Pediatr Surg,2005,40(11):1681-1690.DOI:10.1016/j.jpedsurg.2005.07.052.
24 Putra J,Ornvold K.Undifferentiated embryonal sarcoma of the liver:a concise review[J].Arch Pathol Lab Med,2015,139(2):269-273.DOI:10.5858/arpa.2013-0463-RS.
25 Dickie B,Dasgupta R,Nair R,et al.Spectrum of hepatic hemangiomas:management and outcome[J].J Pediatr Surg,2009,44(1):125-133.DOI:10.1016/j.jpedsurg.2008.10.021.
26 Kuroda T,Hoshino K,Nosaka S,et al.Critical hepatic hemangioma in infants:recent nationwide survey in Japan[J].Pediatr Int,2014,56(3):304-308.DOI:10.1111/ped.12347.
27 George ME,Sharma V,Jacobson J,et al.Adverse effects of systemic glucocorticosteroidtherapy in infants with hemangiomas[J].Arch Dermatol,2004,140(8):963-969.DOI:10.1001/archderm.140.8.963.
28 Leaute-Labreze C,Dumas De La Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.DOI:10.1056/NEJMc0708819.
29 Drolet BA,Frommelt PC,Chamlin SL,et al.Initiation and use of propranolol for infantile hemangioma:report of a consensus conference[J].Pediatrics,2013,131(1):128-140.DOI:10.1542/peds.2012-1691.
30 刘超,张蕾,李香,等.阶梯加量法"口服普萘洛尔"治疗婴幼儿血管瘤疗效分析[J].临床小儿外科杂志,2016,15(6):590-593.DOI:10.3969/j.issn.1671-6353.2016.06.018.Liu C,Zhang L,Li X,et al.Treatment of infantile hemangioma by oral "ladder dosage" propranolol:a study of 56 cases[J].J Clin Ped Sur,2016,15(6):590-593.DOI:10.3969/j.issn.1671-6353.2016.06.018.
31 Prey S,Voisard JJ,Delarue A,et al.Safety of propranolol therapy for severe infantile hemangioma[J].JAMA,2016,315(4):413-415.DOI:10.1001/jama.2015.13969.
32 Kim KH,Choi TH,Choi Y,et al.Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma:a randomized clinical trial[J].JAMA dermatol,2017,153(6):529-536.DOI:10.1001/jamadermatol.2017.0250.
33 Bauman NM,Mccarter RJ,Guzzetta PC,et al.Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas:a randomized clinical trial[J].JAMA Otolaryngol Head Neck Surg, 2014,140(4):323-330.DOI:10.1001/jamaoto.2013.6723.
34 Ji Y,Chen S,Xu C,et al.The use of propranolol in the treatment of infantile haemangiomas:an update on potential mechanisms of action[J].Br J Dermatol,2015,172(1):24-32.DOI:10.1111/bjd.13388.
35 Vergine G,Marsciani A,Pedini A,et al.Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma[J].Horm Res Paediatr,2012,78(4):256-260.DOI:10.1159/000337253.
36 Sciveres M,Marrone G,Pipitone S,et al.Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload[J].J Pediatr Gastroenterol Nutr,2011,53(6):693-695.DOI:10.1097/MPG.0b013e3182201a4e.
37 Konrad D,Ellis G,Perlman K.Spontaneous regression of severe acquired infantile hypothyroidism associated with multiple liver hemangiomas[J].Pediatrics,2003,112(6 Pt 1):1424-1426.
38 Hughes JA,Hill V,Patel K,et al.Cutaneous haemangioma:prevalence and sonographic characteristics of associated hepatic haemangioma[J].Clin Radiol,2004,59(3):273-280.DOI:10.1016/S0009-9260(03)00267-8.
39 Horii KA,Drolet BA,Frieden IJ,et al.Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas[J].Pediatr Dermatol,2011,28(3):245-253.DOI:10.1111/j.1525-1470.2011.01420.x.
40 Vredenborg AD,Janmohamed SR,De Laat PC,et al.Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma[J].Br J Dermatol,2013,169(1):188-191.DOI:10.1111/bjd.12229.
相似文献/References:
[1]秦娜,徐洪军,徐永根,等.先天性心脏病合并肺动脉高压的围术期治疗[J].临床小儿外科杂志,2008,7(03):17.
[2]滕水生 王权发 娄辉 蔡泽平 李红卫 张勤俭 梁振 卢瑶华 王国彦 李祖桂. Ponseti技术治疗婴幼儿先天性马蹄内翻足62例[J].临床小儿外科杂志,2012,11(02):137.
[3]岑卿卿,陈宣锋,林晓曦,等.婴幼儿面部中线型毛细血管畸形的诊疗意义与进展[J].临床小儿外科杂志,2019,18(08):650.[doi:10.3969/j.issn.1671-6353.2019.08.007]
Cen Qingqing,Chen Xuanfeng,Lin Xiaoxi,et al.Advances in the diagnosis and treatment of midline facial capillary malformations in infants[J].Journal of Clinical Pediatric Surgery,2019,18(08):650.[doi:10.3969/j.issn.1671-6353.2019.08.007]
[4]李宗良,马荣欣,魏雁,等.噻吗洛尔外敷联合32P敷贴治疗婴幼儿血管瘤的疗效观察[J].临床小儿外科杂志,2021,20(04):354.[doi:10.12260/lcxewkzz.2021.04.010]
Li Zongliang,Ma Rongxin,Wei Yan,et al.Efficacy of timolol plus 32P applicator brachytherapy for infantile hemangioma[J].Journal of Clinical Pediatric Surgery,2021,20(08):354.[doi:10.12260/lcxewkzz.2021.04.010]
[5]刘祎,秦齐,张佳,等.婴幼儿脑室出血后脑积水的危险因素分析[J].临床小儿外科杂志,2024,(03):242.[doi:10.3760/cma.j.cn101785-202208008-008]
Liu Yi,Qin Qi,Zhang Jia,et al.Analysis of risk factors of hydrocephalus after intraventricular hemorrhage in infants[J].Journal of Clinical Pediatric Surgery,2024,(08):242.[doi:10.3760/cma.j.cn101785-202208008-008]
备注/Memo
收稿日期:2018-09-16。
基金项目:国家自然科学基金资助项目（编号：81401606/81400862）；四川大学优秀青年学者基金资助项目（编号：2015SU04A15）；四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目（编号：2019HXFH056）；四川省科技厅重点研发项目（编号：2019YFS03202）
通讯作者:吉毅,Email:jijiyuanyuan@163.com;陈思源,Email:siy_chen@163.com